Indusatumab vedotin

Indusatumab vedotin is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Seattle Genetics.

Mechanism of Action

Indusatumab vedotin is an antibody-drug conjugate (ADC) that combines an antibody specific for tissue factor (TF), a protein that plays a role in tumor growth and progression, with a potent cell-killing agent. The antibody portion of the ADC binds to TF on the surface of cancer cells, delivering the cell-killing agent directly to the cells.

Clinical Trials

Indusatumab vedotin has been evaluated in several clinical trials for the treatment of various types of cancer. These trials have shown promising results, with some patients experiencing significant reductions in tumor size.

Side Effects

Like all drugs, indusatumab vedotin can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and decreased appetite. More serious side effects can include nerve damage and low blood cell counts.

See Also

• Monoclonal antibodies
• Antibody-drug conjugates
• Tissue factor
• Clinical trials
• Cancer treatment

References

Indusatumab vedotin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski